Inventor · disambiguated record
Michele J. Losman
Also filed as: LOSMAN MICHELE J
6 granted patents·2 pending applications·70 citations·filing 1997–2017
80Inventor score
Files withIMMUNOMEDICS INC8
Top patents by PatentIndex Score
8 records- 0193US9441043B2Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)IMMUNOMEDICS INC·Filed 2015·Granted Sep 13, 2016·7 cites·10 claims
- 0288US6730300B2Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applicationsIMMUNOMEDICS INC·Filed 1997·Granted May 4, 2004·61 cites·12 claims
- 0386US10377829B2Isolated nucleic acid encoding an anti-IGF-1R antibodyIMMUNOMEDICS INC·Filed 2017·Granted Aug 13, 2019·2 cites·11 claims
- 0465US7348419B2Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applicationsIMMUNOMEDICS INC·Filed 2004·Granted Mar 25, 2008·0 cites·9 claims
- 0565US2014086830A1Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)IMMUNOMEDICS INC·Filed 2013·Application pending·0 cites
- 0663US9751948B2Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)IMMUNOMEDICS INC·Filed 2016·Granted Sep 5, 2017·0 cites·20 claims
- 0761US7413736B2Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applicationsIMMUNOMEDICS INC·Filed 2007·Granted Aug 19, 2008·0 cites·3 claims
- 0856US2010226884A1Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)IMMUNOMEDICS INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michele J. Losman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →